These Dividend Kings Have Raised Their Payouts for 60 Years or More.
Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for $2B
Ambrx Snags $2 Billion Takeover, But CEO Dan O'Connor Says Don't Call It 'Hot'
Merck and J&J’s Biotech Deals Are More Good News for a Troubled Sector
Ambrx Snags $2 Billion Takeover, But CEO Dan O'Connor Says Don't Call It 'Hot'
Merck and J&J’s Biotech Deals Are More Good News for a Troubled Sector
Ambrx Biopharma Shares Double on $2B Acquisition by Johnson & Johnson
Johnson & Johnson to Acquire Ambrx for $2 Billion
Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B
Investors Hope the Dogs of the Dow Can Find Their Bite
Trial Lawyers Are Wrecking the Bankruptcy System
Can Obesity Firms Continue Their Outperformance in 2024?
Investors Lose $426 Billion On These 8 Giant Losers This Year
Kenvue's stock rises after favorable court ruling in Tylenol litigation
Johnson & Johnson Earnings to Be Hit by Loss of Stelara Exclusivity, Wells Fargo Says
Microsoft Tops the List of Best-Managed Companies of 2023
Integra LifeSciences to Buy Acclarent From Johnson & Johnson
Walgreens’ stock soars 8% to lead Dow gainers but is still on track for worst year since 1972
These Pharma Stocks Are Just the Medicine
Johnson & Johnson Ticks Higher Following Guidance Release
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.